FDA
-
-
-
-
-
-
-
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
-
-
-
-
-
-
-
Assembly Biosciences (ASMB) Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
-
-
-
-
-
-
-
Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019
-
-
-
-
-
-
-
Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China
-
-
-
-
-
-
-
Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus
-
-
-
-
-
-
-
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection
-
-
-
329,909 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

